Advice on warfarin shortage 2023

Viatris Pty Ltd has advised the Therapeutic Goods Administration (TGA) of shortages of several warfarin products due to manufacturing issues. The shortages currently affect Coumadin (warfarin sodium) 2 mg and 5 mg tablets.

Warfarin is an anticoagulant used to prevent blood from excessive clotting or forming harmful clots for patients at risk of heart attack and stroke. While the two brands of warfarin marketed in Australia (Coumadin and Marevan) are both available in various strengths, they are not bioequivalent and should not be interchanged unless under medical supervision.

The shortage of the Coumadin 5 mg tablets is expected to continue until 31 July 2023. The shortage of the Coumadin 2 mg tablets is expected to continue until 20 March 2023. To minimise disruption to patients, Viatris is working to increase supply of Coumadin 1 mg and 2 mg tablets to allow patients to maintain their prescribed dose using a combination of the lower strengths available, in consultation with a health professional.

The TGA is working closely with Viatris and other stakeholders to minimise the shortage impact and is seeking advice from relevant stakeholders on details to include in a proposed Serious Scarcity Substitution Instrument. The instrument, if made, will allow pharmacists to dispense an alternative strength of the same warfarin brand if the prescribed strength is unavailable.

To ensure access to the limited stock is maintained as widely as possible, the TGA urges pharmacists and consumers not to stockpile Coumadin or Marevan.

The latest information about the shortages and the expected return to supply dates is available on the Medicine Shortage Reports Database- external site on the TGA website.

The TGA is also aware of concerns raised about the new packaging of the warfarin product range (blue bottle presentation) and is working closely with Viatris to further differentiate the different strengths of each product label without disrupting supply.